- Source: Cebaracetam
Cebaracetam (INNTooltip International Nonproprietary Name; developmental code names CGS-25248; ZY-15119) is an experimental drug of the racetam group described as a nootropic which was never marketed.
It is a chlorinated acetylpiperazine-substituted analogue of phenylpiracetam and is also a derivative of RGPU-95 (4-chlorophenylpiracetam). It is the analogue of RGPU-95 in which the terminal amide group has been replaced with a piperazin-2-one moiety. The mechanism of action of cebaracetam is undefined or unknown.
The drug was under development by Novartis for the treatment of cognition disorders by the 1990s but development was discontinued in 1995. It reached phase 2 clinical trials prior to its discontinuation.